Neurotech Pharmaceuticals provided an update on its ongoing transition to a commercial-stage company following the first anniversary of FDA's approval of Encelto (taroretcel-lwey), the company’s encapsulated cell-based gene therapy for adults with idiopathic Macular Telangiectasia Type 2 (MacTel).

The therapy, designed to deliver therapeutic proteins directly to the retina through Neurotech’s encapsulated cell technology platform, marked the first FDA-approved treatment specifically for adults with MacTel Type 2.

According to Neurotech, over the past year, Encelto has continued to be integrated into retina practices across the United States, supported by expanding patient access and established commercial manufacturing capabilities. More than 700 patients have enrolled in ENCELTOconnect, Neurotech’s patient portal, while procedures have surpassed the 100-surgery milestone, including second-eye treatments where clinically appropriate. Several academic medical centers have also added Encelto to their formularies.

Reimbursement progress has also advanced over the past year. A permanent J-Code (J3403) for Encelto took effect on October 1, 2025, supporting billing consistency and payer alignment. To date, 88 medical policies have been established, representing coverage for approximately 200 million covered lives across the United States. Neurotech said the growing payer coverage is helping create more predictable and consistent patient access and treatment planning across a range of practice settings.

The company noted that it maintains established commercial manufacturing capacity designed to support both current and anticipated demand for the therapy. As adoption increases, Neurotech said it will continue focusing on operational execution and support for retina specialists implementing the treatment.

“Since approval, our focus has been disciplined execution, responsible integration, and strong partnership with the retina community,” said Richard Small, Chief Executive Officer of Neurotech Pharmaceuticals. “We are encouraged by how clinicians are incorporating this therapy into practice and by the continued progress in access and clinical adoption. Our priority remains supporting physicians and patients in connection with this debilitating disease.”